lobbying_activities: 2267320

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2267320	8cdcb891-4aff-4e99-94e4-75af88561e3d	Q1	WINNING STRATEGIES WASHINGTON	50796	KALEO	2019	first_quarter	PHA	Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues	HOUSE OF REPRESENTATIVES,SENATE	40000		0	0	2019-04-16T13:28:23.483000-04:00